Skip to Content

NORML Blog

Syndicate content
Working to reform marijuana laws
Updated: 16 hours 38 min ago

Study: No Increase In Problematic Cannabis Use By Young People Following Changes In Marijuana’s Legal Status

Tue, 07/11/2017 - 14:07

Yet another study has once again affirmed that the regulation of marijuana for medical or recreational purposes is not associated with increases in problematic cannabis use by young people.

Writing in the Journal of Clinical Psychiatry, federal investigators from the US National Institute on Drug Abuse and the Substance Abuse Mental Health Services Administration evaluated marijuana use rates among young people (ages 12 to 17) between the years 2002 and 2014.

Researchers reported that the prevalence of past-year cannabis use by youth fell 17 percent during this time period. The prevalence of problematic use by young people fell by 25 percent – with a downward trend starting in 2011.

“In the United States, compared to 2002, even after adjusting for covariates, cannabis use decreased among youth during 2005-2014, and cannabis use disorder declined among youth cannabis users during 2013-2014,” authors concluded.

The study’s findings are consistent with those of numerous other papers reporting no uptick in youth marijuana use or abuse following the enactment of marijuana regulation, including those here, here, here, here, here, here, and here.

An abstract of the study, “Cannabis use and cannabis use disorders in the United States, 2002-2014,” appears online here.

Categories: Blog Feeds

Study: Alcohol Use, But Not Cannabis, Associated With Changes In Brain Structure

Tue, 07/11/2017 - 11:57

Alcohol consumption is associated with negative changes in gray matter volume and in white matter integrity, while cannabis use is not, according to data published online ahead of print in the journal Addiction.

Investigators from the University of Colorado, Boulder and the Oregon Health & Science University evaluated neuroimaging data among adults (ages 18 to 55) and adolescents (ages 14 to 18). Authors identified an association between alcohol use and negative changes in brain structure, but identified no such association with cannabis.

“Alcohol use severity is associated with widespread lower gray matter volume and white matter integrity in adults, and with lower gray matter volume in adolescents,” they concluded. By contrast, “No associations were observed between structural measures and past 30-day cannabis use in adults or adolescents.”

Researchers acknowledged that their findings were similar to those of prior studies “suggesting that regionally specific differences between cannabis users and non-users are often inconsistent across studies and that some of the observed associations may actually be related to comorbid alcohol use.”

A 2015 brain imaging study published in The Journal of Neuroscience similarly reported that cannabis use was not positively associated with adverse changes in the brain, but that alcohol “has been unequivocally associated with deleterious effects on brain morphology and cognition in both adults and adolescents.”

Longitudinal data published in June in the British Medical Journal reported, “Alcohol consumption, even at moderate levels, is associated with adverse brain outcomes including hippocampal atrophy.”

An abstract of the study, “Structural Neuroimaging Correlates of Alcohol and Cannabis Use in Adolescents and Adults,” appears online here.

Categories: Blog Feeds

DEA Reaffirms Stance That CBD Meets Schedule I Criteria — Reality Says Otherwise

Mon, 07/10/2017 - 15:25

The US Drug Enforcement Administration has publicly reiterated its position that cannabidiol, a non-psychotropic cannabinoid, is properly categorized under federal law as a schedule I controlled substance — meaning that, by definition, it possesses “a high potential for abuse,” “no currently accepted medical use in treatment in the United States,” and lacks “accepted safety … under medical supervision.”

The agency has long contended that CBD, along with all organic cannabinoids, is — by default — a schedule I controlled substance because it is a naturally occurring component of the cannabis plant. (This position is similarly held by both the NIDA and the FDA.) Nonetheless, a growing body of science undermines the notion that CBD meets any of the criteria necessary for such classification.

Specifically, clinical trial data finds that CBD is “safe,” “non-toxic,” and “well tolerated” in human volunteers. Even the director of the US National Institute on Drug Abuse acknowledges that CBD is “not mind-altering” and that it “appears to be a safe drug with no addictive effects.”

Recently conducted controlled studies also acknowledge its therapeutic efficacy, particularly the ability of CBD dosing to mitigate treatment-resistant seizures, hypertension, and psychotic symptoms in humans. Other peer-reviewed data shows that CBD therapy holds promise for the treatment of “Parkinson’s disease, Alzheimer’s disease, cerebral ischemia, diabetes, rheumatoid arthritis, other inflammatory diseases, nausea and cancer.”

That is why in addition to the thirty states that presently recognize medical cannabis, an additional 16 states also explicitly recognize the use of CBD as a viable medical treatment.

Nonetheless, it remains unlikely that the DEA is going to amend its position any time soon. Further, police in recent months have begun initiating raids of CBD retailers, such as those reported here, here, and here. That is why it is critical that members of Congress move forward with legislation to remove the cannabis plant from the Controlled Substances Act.

Presently, several pieces of federal legislation are pending to amend the federal classification of CBD as a schedule I substance. These include:

HR 2020: Passage of this act would exclude CBD from the federal definition of ‘marihuana.’

S. 1374/HR 2920: Passage of these Acts would exempt from federal prosecution those who are engaged in state-sanctioned medical cannabis activities; it would also remove CBD from the federal definition of ‘marihuana.’

HR 2273/S. 1008: Passage of these Acts would exclude CBD and CBD-rich cannabis plants from the federal definition of ‘marihuana.’

You can contact your members of Congress in support of these bills and other pending legislation by visiting NORML’s Take Action Center here.

Categories: Blog Feeds

Florida: Lawsuit Filed Challenging Medical Cannabis Smoking Ban

Thu, 07/06/2017 - 16:36

Representatives of Florida for Care filed litigation today challenging a statewide ban on medical cannabis smoking. The suit was expected after lawmakers approved legislation (SB 8A) in June amending Amendment 2 — a voter initiated constitutional amendment permitting the use and distribution of medical cannabis. Seventy-one percent of voters approved the amendment in November.

Senate Bill 8A amends the definition of medical cannabis in a manner that prohibits “marijuana in a form for smoking” and that bars the personal possession of herbal cannabis flowers, except in instances where they are contained “in a sealed, tamper-proof receptacle for vaping.” The Florida for Care suit argues that these changes inconsistent with the constitutional definition of marijuana, as passed by voters, and therefore should not be implemented.

The lawsuit argues, “Inhalation is a medically effective and efficient way to deliver tetrahydrocannabinol (THC), and other cannabinoids, to the bloodstream. … By redefining the constitutionally defined term ‘medical use’ to exclude smoking, the Legislature substitutes its medical judgment for that of ‘a licensed Florida physician’ and is in direct conflict with the specifically articulated Constitutional process.”

Under the revised law, patients diagnosed with cancer, epilepsy, glaucoma, HIV/AIDS, PTSD, ALS, Crohn’s disease, Parkinson’s disease, or multiple sclerosis — or who suffer from chronic pain related to any of these diseases — are eligible to receive a 70-day supply of cannabis-infused oils or edible products from a limited number of state-licensed dispensing facilities.

NORML has long argued against regulations that limit or prohibit patients’ access to whole-plant cannabis in lieu of cannabis-derived extracts or pills. Cannabis inhalation is not associated with increased instances of lung cancer, COPD, or other tobacco-related adverse effects on pulmonary function. Inhaled cannabis is fast acting and permits patients to accurately self-regulate their dose. By contrast, non-herbal forms of cannabis possess delayed onset and their effects can often be far less predictable than those of herbal cannabis. Many patients seeking rapid relief of symptoms do not benefit from pills, tinctures, or edibles, and such restrictions unnecessarily limit patients’ choices.

If the court invalidates SB 8A, the task of writing the rules for implementing the initiative — which must be operational by October — will fall to the Florida Department of Health.

Categories: Blog Feeds

Two New Virginia Laws Foreshadow Larger Cannabis Policy Changes

Thu, 07/06/2017 - 15:44

A common cliché for overcoming a difficult obstacle asks, “how do you eat an elephant?” The answer is, “one bite at a time.” In Virginia politics, the tough question facing cannabis policy reform advocates is, “how do you change the minds of political Elephants?” The answer is, “one law at a time.” Although progress in cannabis reform has been slow in Virginia, two recent bills signed by Governor Terry McAuliffe are significant signs that change is coming, and quicker than ever before.

Ending Automatic Driver’s License Suspension for Cannabis Possession

In May 2017, Gov. McAuliffe had a signing ceremony for Senator Adam Ebbin’s Senate bill 784 and Delegate Les Adams’ House bill 2051. These companion bills ended the absolute requirement that Virginians convicted of marijuana possession lose their driver’s license. Until this change, which takes effect July 1, the judge had no option but to suspend, even if the offense was totally unrelated to a vehicle. A driver’s license is necessary in commuter-based economies such as Virginia, where most residents work, attend school, receive medical treatment, or worship outside of their home city, and the public transportation is less then reliable.

Virginia NORML led the lobbying for this bill, and helped sway lawmakers in the General Assembly who were wary of the proposed changes. The legislators were convinced by explaining the law in detail, and highlighting the positive results from allowing individuals to maintain their license for work and education – no extreme rhetoric or exaggeration needed. Ryan Johnson, membership coordinator for Virginia NORML, testified for both pieces of legislation was congratulated by many thankful legislators at the ceremony.

Gov. Terry McAuliffe (VA-D) and Ryan Johnson

Ryan Johnson with Delegate Les Adams (R-16)

“With Virginia NORML’s guidance, I was able to craft impactful testimony, helping pass meaningful legislation that will make a difference for thousands of Virginians,” said Ryan Johnson at Gov. McAuliffe’s ceremony. “I was humbled by how many legislators thanked me for stepping outside of my comfort zone and sharing my story in the 2017 General Assembly.” 

Del. Paul Krizek (D-44), Del. Les Adams (R-16) ,Sen. Scott Surovell (D-36), Del. Alfonso Lopez (D-49), Ryan Johnson, Sen. Adam Ebbin (D-30)

Watch the video

The new law is a significant step for cannabis policy reform in Virginia for two reasons. First, this is one of the very few marijuana-related criminal justice reforms that advocates have successfully pushed through the difficult, Republican-controlled House subcommittees. Those subcommittees are the sticking point for most criminal justice reform legislation, the bottle neck that prevents bills from proceeding to a full House vote. Second, this is important because it allows judges discretion to apply the standard first-offender’s program and community service to an adult discovered possessing cannabis somewhere completely removed from any vehicles. Admittedly, this is a small step. However, every step, even the very small ones, put Virginia closer to a more sensible criminal justice system that does not criminalize marijuana possession or consumption.

Welcome to the Medical Cannabis States Club, Virginia

In June 2017, Gov. McAuliffe had another bill signing ceremony, this one for Senator Marsden’s Senate bill 1027. This bill is significant because it officially makes Virginia a medical cannabis state. Medical cannabis dispensaries will be called “pharmaceutical processors,” and will become medical cannabis patients’ legal source of the cannabis oil permitted under Virginia law. The processors will be vertically integrated facilities. That means the plants will be grown, cured, and trimmed onsite; all extraction, distillation, and synthesis of custom biopharmaceutical medicines will be done in the on-site laboratory; and, finally, patients will interact with and receive medication from a pharmacist. Unlike the medical cannabis dispensaries in Colorado, this will more closely resemble a traditional pharmacy.

Virginia families were instrumental in getting this landmark legislation passed. However, despite the great success, the law has serious shortcomings. There will only be five (5) pharmaceutical processors. This places a huge burden on applicants, financially and logistically, and could result in the exclusion of start-up ventures owned by minorities, women, and veterans without access to large capital resources. Second, the related laws allowing patient access to medical cannabis is very short: one (1). Only one patient group, those with intractable epilepsy, can possess medical cannabis oil. The major legislative goal for the 2018 session is the “Let Doctors Decide” bill, which would end the eugenics-style creation of state-permitted patient groups and instead allow trained medical professionals to decide if cannabis would be effective for the individual patient’s treatment plan. Jenn Michelle Pedini was at the ceremony representing Virginia NORML, and spoke to the families of several epilepsy patients and lawmakers who had supported the bill.

Sen. Dave Marsden (D-37) and many families watch as Gov. McAuliffe signs historic medical cannabis legislation. Photo courtesy Michaele White, Governor’s Office.

“It was an exciting day for the families who spent hours at the General Assembly gaining support for this bill which passed unanimously in both the House and Senate. We are looking forward to continuing this path next year and expanding the current law to include all patients for whom medical cannabis would provide relief,” said Beth Collins, Senior Director Government Relations and External Affairs at Americans for Safe Access, and mother of a child with intractable epilepsy.

These landmark bills are significant signs of the change coming in Virginia’s cannabis policy. Decriminalization is being studied by the State Crime Commission, following a request by Senate Majority leader Tommy Norment. The Driver’s License bill may be the first overly punitive prohibition measure to fall, and like dominoes, the changes to criminal justice reform will gain momentum and culminate in decriminalization of adult cannabis possession within the next couple years. The pharmaceutical processor bill is a huge hurdle for both patients seeking legal access to medical cannabis medications, and for individuals interested in the regulated cannabis industry. Although Virginia’s cannabis industry will fall under heavy regulation and oversight by the Commonwealth, the new industry presents new opportunities, jobs, and tax revenue.

Virginia NORML is the leading cannabis law reform organization in Virginia, but we can only continue our success in changing outdated laws with your help! The Summer of Change Campaign is currently underway, and we are trying to raise $42,000 to support our efforts in the 2018 session and the push for “Let Doctors Decide.” Virginia has a major election this year, and the outcome could determine the success – or failure – of our efforts. Donate today to the Summer of Change campaign! With your help, Virginia NORML will continue its track record of success in Richmond bringing marijuana policy reform.

Categories: Blog Feeds

Study: Crimes Spike Following Closing of Dispensaries

Wed, 07/05/2017 - 15:59

The closure of medical marijuana dispensaries is associated with an increase in larceny, property crimes, and other criminal activities, according to data published in the Journal of Urban Economics.

Researchers at the University of Southern California and the University of California, Irvine assessed the impact of dispensary closures on neighborhood crimes rates in the city of Los Angeles. Investigators analyzed crime data in the days immediately prior to and then immediately after the city ordered several hundred operators to be closed. Authors reported an immediate increase in criminal activity – particularly property crime, larceny, and auto break ins – in the areas where dispensary operations were forced to close as compared to those neighborhoods were dispensaries remained open.

“[W]e find no evidence that closures decreased crime,” authors wrote. “Instead, we find a significant relative increase in crime around closed dispensaries.” Specifically, researchers estimated that “an open dispensary provides over $30,000 per year in social benefit in terms of larcenies prevented.”

They concluded, “Contrary to popular wisdom, we find an immediate increase in crime around dispensaries ordered to close relative to those allowed to remain open. The increase is specific to the type of crime most plausibly deterred by bystanders, and is correlated with neighborhood walkability. … A likely … mechanism is that ‘eyes upon the street’ deter some types of crime.”

The findings are consistent with those of prior studies determining that dispensary operations are not associated with ‘spillover effects’ in local communities, such as increased teen use or increased criminality.

An abstract of the study, “Going to pot? The impact of dispensary closures on crime,” appears online here.

Categories: Blog Feeds

Study: Cannabinoids Reduce Migraine Frequency

Wed, 07/05/2017 - 12:01

The prolonged daily administration of cannabinoids is associated with a reduction in migraine headache frequency, according to clinical trial data presented at the 3rd Congress of the European Academy of Neurology.

Italian researchers compared the efficacy of oral cannabinoid treatments versus amitriptyline – an anti-depressant commonly prescribed for migraines – in 79 chronic migraine patients over a period of three months. Subjects treated daily with a 200mg dose of a combination of THC and CBD achieved a 40 percent reduction in migraine frequency – a result that was similar to the efficacy of amitriptyline therapy.

Subjects also reported that cannabinoid therapy significantly reduced acute migraine pain, but only when taken at doses above 100mg. Oral cannabinoid treatment was less effective among patients suffering from cluster headaches.

“We were able to demonstrate that cannabinoids are an alternative to established treatments in migraine prevention,” researchers concluded.

Some five million Americans are estimated to experience at least one migraine attack per month, and the condition is the 19th leading cause of disability worldwide.

According to retrospective data published last year in the journal Pharmacotherapy, medical cannabis consumption is often associated with a significant decrease in migraine frequency, and may even abort migraine onset in some patients.

A just published review of several studies and case-reports specific to the use of cannabis and cannabinoids in the journal Cannabis and Cannabinoid Research concludes: “[I]t appears likely that cannabis will emerge as a potential treatment for some headache sufferers.”

An abstract of the study, “Cannabinoids suitable for migraine prevention,” appears online here.

Categories: Blog Feeds

Have a NORML 4th of July

Tue, 07/04/2017 - 07:00

What are your plans this Fourth of July weekend? If you are like most Americans, you are likely to be having a cookout, watching fireworks with friends and family, or engaging in some other social event that celebrates your freedom.

But for the millions of Americans who consume cannabis, freedom can be fleeting.

In many states, our fellow citizens still face the possibility of arrest, criminal prosecution, and jail time for a first offense marijuana possession charge. For instance, in Arizona and Florida, first-time possession offenders may face felony charges. In Oklahoma, growing even a single plant is punishable by up to life in prison.

At NORML we understand that this harsh reality is probably not something that you think about every single day — particularly on July 4th. But we do. That is why we are working hard to empower our national network of engaged citizens — citizens like you — to change America’s antiquated and punitive marijuana laws. And, because of you and your efforts, we are succeeding!

Support NORML’s effort to empower citizens to participate in the democratic process and reform our nation’s marijuana laws.

It is the highest ideal of American democracy that our nation has a well-informed and politically engaged electorate. That is why every week — via our blog, social networks, and weekly e-zine — NORML aims to arm our supporters with the latest science and news, as well as legislative and legal developments pertaining to cannabis and cannabis policy. Via the NORML Action Center at www.norml.org/act, we keep you up to date on and engaged in all ongoing state and federal legislative efforts to reform marijuana prohibition and restore our freedoms. And we thank the 100,000+ individuals that have taken action over the past few months.

Now, more than ever, it is crucial that we come together and assert our authority over our elected officials. The Declaration of Independence explicitly states: That to secure these rights, Governments are instituted among Men, deriving their just powers from the consent of the governed.

In sum: it’s our responsibility to compel our elected officials to institute change.

Tens of thousands of NORML people just like you support our mission. Make a contribution today so that we can continue our important work.

Our system of government is not perfect. In fact, it is far from it. But for hundreds of years, citizens have organized and struggled to come closer to Thomas Jefferson’s iconic aspiration, “That all men are created equal; that they are endowed by their Creator with certain unalienable Rights; that among these are Life, Liberty and the pursuit of Happiness.

Thomas Jefferson legally grew cannabis. You should be able to as well.

Help us change American for the better.

Happy Fourth of July,
The NORML Team

Categories: Blog Feeds

Setting The Record Straight

Sun, 07/02/2017 - 08:12

One of NORML’s primary missions is to move public opinion sufficiently to legalize the responsible use of marijuana by adults. One of the ways we successfully achieve this goal is by debunking marijuana myths and half-truths via the publication of timely op-eds in online and print media. Since the mainstream media seldom casts a critical eye toward many of the more over-the-top claims about cannabis, we take it upon ourselves to set the record straight.

The majority of NORML’s rebuttals are penned by Deputy Director Paul Armentano. In the past few weeks, he has published numerous op-eds rebuking a litany of popular, but altogether specious claims about the cannabis plant.

Below are links to a sampling of his recent columns.:

“Cannabis mitigates opioid abuse — the science says so”
in Santa Fe New Mexican

“Is big alcohol taking a hit from legal weed?”
in Salon

“Can marijuana help mitigate America’s opioid crisis?”
in The Hill

“The Deputy Attorney General is ignorant to the science of medical marijuana”
in The Daily Caller

“The DEA says ‘marijuana is not medicine’ — reality says otherwise”
in The Hill

For a broader sampling of NORML-centric columns and media hits, please visit NORML’s ‘In the Media’ archive here.

If you see the importance of NORML’s educational and media outreach efforts, please feel free to show your support by making a contribution here.

Categories: Blog Feeds

Weekly Legislative Update 7/1/17

Sat, 07/01/2017 - 07:30

Welcome to this week’s edition of the NORML legislative roundup!

At the federal level, the House Appropriations Committee this week released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.

The text of this amendment has never been included in the base bill of the CJS Appropriations bill. In every case of its passage, lawmakers have needed to add the language as a separate rider to the legislation and then vote on it on the floor of the House.

This year is no exception. Our allies in Congress anticipate a similar process to take place this fall and they are confident that we will once again be victorious — despite the best efforts of our opponents.

At the state level, the biggest development has been the introduction of Wisconsin Senate Bill 318, to amend state law so that marijuana possession offenses (up to 10 grams) are reduced to a civil offense, punishable by a fine of $100, and no longer have the threat of jail time.

As we prepare for the Fourth of July celebration, it’s always good to have some critical self-reflection about how our democracy is functioning. Our system of government is not perfect – in fact, it is far from it. But for hundreds of years, citizens have organized and struggled to come closer to Thomas Jefferson’s iconic aspiration, “That all men are created equal; that they are endowed by their Creator with certain unalienable Rights; that among these are Life, Liberty and the pursuit of Happiness.

Thomas Jefferson legally grew cannabis. You should be able to as well.

Following are the bills from around the country that we’ve tracked this week and as always, check http://norml.org/act for legislation pending in your state.

Don’t forget to sign up for our email list and we will keep you posted as these bills and more move through your home state legislature and at the federal level.

Thanks for all you do and keep fighting,
Justin

Priority Alerts

Federal

Protect Lawful Medical Marijuana Programs: The House Appropriations Committee released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.

Click here to send a message to your federal elected officials to maintain existing protections from the Justice Department.

Join The Caucus: With public support for reforming marijuana laws at an all time high, Reps. Earl Blumenauer (D-OR), Dana Rohrabacher (R-CA), Jared Polis (D-CO), and Don Young (R-AK) earlier this year formed the Congressional Cannabis Caucus to develop and promote sensible cannabis policy reform and work to ease the tension between federal and state cannabis laws.

Click here to email your Member of Congress to urge them to join the Congressional Cannabis Caucus

California

Legislation is pending, Assembly Bill 1578, to try and limit potential federal interference in the state’s marijuana regulatory laws.

The bill states, “This bill would prohibit a state or local agency, as defined, from taking certain actions without a court order signed by a judge, including using agency money, facilities, property, equipment, or personnel to assist a federal agency to investigate, detain, detect, report, or arrest a person for commercial or noncommercial marijuana or medical cannabis activity that is authorized by law in the State of California and transferring an individual to federal law enforcement authorities for purposes of marijuana enforcement.”

Update: AB-1578 was passed by members of the Senate Public Safety Committee on June 27 by a 5-2 vote.

CA resident? Click here to send your lawmakers a message in support of AB-1578

Delaware

Senate Bill 24, introduced by Senate Majority Leader Margaret Rose Henry to expand the list of qualifying conditions to medical marijuana to include PTSD.

On June 22 Senate Bill 24 was passed the Health & Human Development Committee in statehouse.

DE resident? Click here to send a message to your lawmakers in support of this effort. 

Wisconsin

Senate Bill 318 has been introduced to amend state law so that marijuana possession offenses (up to 10 grams) are reduced to a civil offense, punishable by a fine of $100.

The policy proposed by this bill is line with those of numerous other states, including Nebraska and Ohio. Such a change will save taxpayers money and allow police and the courts to re-prioritize their resources toward addressing more serious crimes.

WI resident? Click here to send a message to your lawmakers in support of decriminalization

Categories: Blog Feeds

Nevada: Licensed Adult Use Marijuana Sales Set To Begin Saturday

Fri, 06/30/2017 - 08:46

Starting on Saturday, July 1, specially licensed medical cannabis dispensaries in Nevada will have the opportunity to engage in the retail sale of marijuana to adults.

State tax regulators finalized temporary rules on Monday governing adult use sales. Regulators so far have issued over 80 licenses to business establishments seeking to engage in activities specific to the production, testing, or sale of cannabis to adults.

“Adults in Nevada will now be able to access cannabis in a safe, above ground, regulated environment,” NORML Political Director Justin Strekal said. “To their immense credit, lawmakers expeditiously to implement the will of their voters. Elected officials elsewhere would do well to follow Nevada’s example.”

Adult use sales are anticipated to be limited because of an ongoing legal dispute regarding who may legally transport cannabis to retail stores. Last week, a Carson City judge issued an injunction prohibiting any entity other than liquor distributors from engaging in retail marijuana transport. As a result, retailers will only be able to sell their existing inventory.

“While we applaud Nevada for moving to enact their voter approved legalization initiative in a timely fashion, interested parties must now move quickly and decisively to resolve the pending issues around distribution. If supply remains constrained in the state it will drive up prices and ultimately lead to most retail outlets being entirely out of sellable product for the recreational market.” NORML Executive Director Erik Altieri said. “This will only serve to continue to drive consumers to the black market, the very thing residents voted to demolish, and will deprive the state of needed tax revenue that will instead go to underground operators.”

A majority of voters decided in November in favor of the Regulation and Taxation of Marijuana Act – a voter-initiated regulating the adult use marijuana market. In May, state regulated decided in favor of expediting the timeline for retail marijuana sales from January 1, 2018 to July 1, 2017.

Seven additional states — Alaska, California, Colorado, Maine, Massachusetts, Oregon, and Washington — no longer impose criminal penalties with regard to the adult possession or use of cannabis.

Businesses in the state still do not have protections from the Justice Department, led by militant prohibitionist Attorney General Jeff Sessions, who recently stated marijuana is “only slightly less awful” than heroin.

You can click here to easily send a message to your federal lawmakers in support of pending legislation, HR 1227: The Ending Federal Marijuana Prohibition Act by clicking HERE.

Categories: Blog Feeds

Will the House of Representatives Let Jeff Sessions Shut Down Medical Marijuana?

Thu, 06/29/2017 - 12:55


This week, the House Appropriations Committee released its 2018 Commerce, Justice, Science (CJS) Appropriations bill, which determines the funding levels for numerous federal agencies, including the Department of Justice. Predictably, the bill does not include language — known as the Rohrabacher-Blumenauer amendment — limiting the Justice Department from taking action against state-sanctioned medical cannabis producers, retailers, or consumers.

Although the amendment was reauthorized by Congress in May, US Attorney General Jeff Sessions has been aggressively lobbying leadership to ignore the provisions. President Trump also issued a signing statement objecting to the Rohrbacher-Blumenauer provision.

Nonetheless, support for the Rohrbacher-Blumenauer protection amendment has only grown in recent years. House members initially passed the amendment as a budgetary rider in 2014 by a vote of 219 to 189. By the following year, 242 House members voted in support of the language.

Yet even with bipartisan support, the text of this amendment has never been included in “the inline text” or “the base bill” of the CJS Appropriations bill. In every case of its passage, lawmakers have needed to add the language as a separate rider to the legislation and then vote on it on the floor of the House.  

This year is no exception. Our allies in Congress anticipate a similar process to take place this fall and they are confident that we will once again be victorious — despite the best efforts of our opponents.

Reps. Blumenauer and Rohrbacher last night in a statement:

“The policy championed by Representatives Blumenauer and Rohrabacher that prevents the Department of Justice from interfering in the ability of states to implement legal medical marijuana laws (previously known as “Rohrabacher-Farr”) has never been included in the base Commerce, Justice, Science, and Related Agencies (CJS) Subcommittee Appropriations bill. Rather, in previous years, Congress has amended the base CJS bill to include these protections.

We are exactly where we thought we would be in the legislative process and look forward to amending the underlying bill once again this year to make sure medical marijuana programs, and the patients who rely on them, are protected. Voters in states across the country have acted to legalize medical marijuana. Congress should not act against the will of the people who elected us.”

Thirty states now permit the doctor-authorized use of medical cannabis by statute, and an additional 16 states include statutory protections for the use of CBD. It is hard to imagine a scenario where a majority of lawmakers from these jurisdictions would vote against the best interests of their constituents, given the broad and bipartisan support that the amendment has received in the past.

It has been and will continue to be in politicians’ best interests to protect this progress and to protect voters’ freedoms from the encroachment of Jeff Sessions and the Justice Department.

Click here to send a message to your member urging them to support the Rohrabacher-Blumenauer amendment.

Then click here to tell them to go one step further by urging them to support the newly introduced CARERS Act of 2017 which will codify these protections into law so that we no longer have to have these annual budget fights.

 

Categories: Blog Feeds

Study: Patients Report Substituting Cannabis For Opioids, Other Pain Medications

Wed, 06/28/2017 - 16:09

Pain patients report successfully substituting cannabis for opioids and other analgesics, according to data published online in the journal Cannabis and Cannabinoid Research.

Researchers from the University of California, Berkeley and Kent State University in Ohio assessed survey data from a cohort of 2,897 self-identified medical cannabis patients.

Among those who acknowledged having used opioid-based pain medication within the past six months, 97 percent agreed that they were able to decrease their opiate intake with cannabis. Moreover, 92 percent of respondents said that cannabis possessed fewer adverse side-effects than opioids. Eighty percent of respondents said that the use of medical cannabis alone provided greater symptom management than did their use of opioids.

Among those respondents who acknowledged having recently taken nonopioid-based pain medications, 96 percent said that having access to cannabis reduced their conventional drug intake. Ninety-two percent of these respondents opined that medical cannabis was more effective at treating their condition than traditional analgesics.

Authors concluded: “[M]ore people are looking at cannabis as a viable treatment for everyday ailments such as muscle soreness and inflammation. … [T]his study can conclude that medical cannabis patients report successfully using cannabis along with or as a substitute for opioid-based pain medication.”

The study’s conclusions are similar to those of several others, such as these herehereherehere, and here, finding reduced prescription drug use and spending by those with access to cannabis. Separate studies report an association between cannabis access and lower rates of opioid-related abuse, hospitalizations, traffic fatalities, and overdose deaths.

Full text of the study, “Cannabis as substitute for opioid-based pain medication: patient self-report,” appears online here.

Categories: Blog Feeds